基因克隆服務的全球市場：市場規模和份額分析（按服務、按應用、按基因類型、按最終用戶）、行業需求預測（截至 2030 年）

市場概況

2023年全球基因克隆服務市場規模預估為31.541億美元，2024年至2030年複合年增長率為18.1%，預計到2030年將達到100.196億美元。

慢性病的增加、對精準藥物的需求增加以及遺傳疾病的顯著發病率預計將有助於該行業的發展。 此外，政府支出的增加、生物技術領域的研發以及遺傳學技術的進步預計將導致製藥領域的研究大幅成長，從而在未來幾年增加行業收入。

關鍵見解

2023年，基因合成品類將佔產業份額45□□%。 它的流行得益於其在眾多垂直領域的廣泛應用以及全球研究活動的成長。

2023年，基因治療將佔產業份額35%。 它的成長潛力在於它能夠治療以前無法治癒的疾病。

由於生物技術和製藥行業的積極研發，截至 2023 年，北美地區佔據該行業最大份額，約為 55%。

本報告分析了全球基因克隆服務市場，包括市場的基本結構和最新情況、主要促進和限制因素以及全球、按地區、主要國家（貨幣單位）的市場規模前景。按服務、應用、基因類型和最終用戶劃分的詳細趨勢、市場競爭的現狀以及主要公司的概況。

目錄

第1章研究範圍

第2章研究方法

第 3 章執行摘要

第 4 章市場指標

第5章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/挑戰
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第6章世界市場

• 摘要
• 市場收入：依服務劃分（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：依基因類型劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：按地區劃分（2017-2030 年）

第7章北美市場

• 摘要
• 市場收入：依服務劃分（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：依基因類型劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第11章中東及非洲市場

第12章美國市場

• 摘要
• 市場收入：依服務劃分（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：依基因類型劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）

第13章加拿大市場

第14章德國市場

第15章法國市場

第16章英國市場

第17章義大利市場

第18章西班牙市場

第19章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其提供的產品/服務的列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• Thermo Fisher Scientific Inc.
• Genscript Biotech Corporation
• Eurofins Scientific SE
• Charles River Laboratories International Inc.
• Takara Bio Inc.
• Creative Biogene
• Synbio Technologies
• Aragen Life Sciences Ltd.
• Sino Biological Inc.
• Curia Global Inc.

第31章 附錄

Market Overview

The market value of global gene cloning services is estimated to be USD 3,154.1 million in 2023 and is projected to reach USD 10,019.6 million by 2030, with a Compound Annual Growth Rate (CAGR) of 18.1% during the period from 2024 to 2030.

The rising occurrence of chronic illnesses, the growing need for accurate drugs, and the substantial occurrence of inherited conditions are projected to contribute to the development of the industry. Moreover, the substantial surge in research in the medicinal field because of the rise in spending by governments, the development of the biotechnological sector, and technical improvements in genetics are projected to propel the industry revenue in the coming years.

Nowadays we see a growing trend of a sedentary way of life, which goes with alcohol consumption, increased smoking, terminal fast food, and exercise too rare. The adoption of this unhealthy diet is causing the state of health of people to be even more unhealthy and also the development of many long-term diseases.

Diseases make things worse and serious diseases will be the things that can even end the life of a person. This therefore led to an increase in the need for such methods of treatments that are either more efficient or more effective in curing the disease.

Key Insights

In 2023, the gene synthesis category grips the dominating industry share of 45%.

Its acceptance stems from its extensive application in numerous verticals and the growing research activities globally.

Researchers are progressively using gene synthesis along with techs such as CRISPR genome editing and synthetic biology for enhanced solutions in life sciences.

Gene synthesis can be used in the fields of neurosciences, therapeutic antibody structure development, plant biology, cancer biology, genetics, and biochemistry.

Initially, it is considered a tool pushed to the front for economical tasks of the traditional cloning and molecular biology method that sometimes need time and are expensive.

In 2023, gene therapy grips a leading industry share of 35%.

Its potential lies in its capability to cure previously irredeemable ailments or diseases.

More than 50,000 inherited illnesses caused by gene mutations have been recognized, making gene treatment a promising method.

Understanding protein pathways and gene expression allows for the testing and effectiveness of more therapies.

In 2023, the North American region holds the largest industry share of approximately 55% because of substantial R&D in the biotechnology and pharmaceutical industries.

Reasons contributing to this comprise the high occurrence of chronic illnesses, a strong healthcare system, and acceptance of enhanced technologies.

Top biotechnology businesses and genomic research projects with significant investments are propelling industry development.

Positive perceptions of health and genetic testing to individuals may stimulate research of genomics in medicine to evaluate therapeutic purposes.

Due to the well-established healthcare, general public knowledge, and individual capacity of a modern person to cover the expenses related to treatment, and along with the implementation of gene therapies for cancer, Canada provides the largest market share in North America.

Enhanced healthcare coverage as well as steady improvement of pharmaceutical and biotech industries is going to result in a substantial portion in the forecast. Additionally, rising chronic diseases, and growing gene cloning in diagnostic and drug development, will support Europe in ranking within the top five markets.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by service
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by gene type
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Service (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by Gene Type (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Service (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by Gene Type (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Service (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by Gene Type (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Service (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by Gene Type (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Service (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by Gene Type (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Service (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by Gene Type (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Service (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by Gene Type (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Service (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by Gene Type (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Service (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by Gene Type (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Service (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by Gene Type (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Service (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by Gene Type (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Service (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by Gene Type (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Service (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by Gene Type (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Service (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by Gene Type (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Service (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by Gene Type (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Service (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by Gene Type (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Service (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by Gene Type (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Service (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by Gene Type (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Service (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by Gene Type (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Service (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by Gene Type (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Service (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by Gene Type (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Service (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by Gene Type (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Service (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by Gene Type (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Thermo Fisher Scientific Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Genscript Biotech Corporation
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Eurofins Scientific SE
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Charles River Laboratories International Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Takara Bio Inc.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Creative Biogene
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Synbio Technologies
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Aragen Life Sciences Ltd.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Sino Biological Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Curia Global Inc.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports